SecBot SecBot

NERV

Minerva Neurosciences, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. MA· CIK 0001598646 Biotech & Drug Discovery
$2.19 −0.11 (−4.74%)
Oct 26 4:00 PM ET · prev $2.30
Market cap
$114.6M
Micro cap
Consensus
Buy
78% Buy or better · 9 analysts
Median target
$10.00
+356% · range $7.00–14.00
Next earnings
Nov 11
in 16 days · EPS est. −$0.18
1 year
−51.6%
from $4.53 · Oct 27
30 days
−35.6%
from $3.40
52-week range
$2.19–8.07
at the low
Avg volume 20D
123.7K
shares / day
Short interest
2.44M
≈5.1% of shares · +0.6%
Days to cover
13.0
at average volume
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read MIXED 2 reports · 90 days
Balance 0 bearish · 0 bullish · 2 neutral oldest → newest, height = score
Avg score ·High conf. 2/2 ·Next Earnings date, Nov 11, 2026
Strongest NEUTRAL Minerva Neurosciences reported Q2 2026 financial results with a GAAP net income of $17.5M driven by a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsBULLISH

    Q2 2026: 9 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    7 of 9 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.225 → −$0.180 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersSTEADY

    Short interest +0.6% to 2.44M shares. 13.0 days to cover, ≈5.1% of shares.

  • TrendDOWNTREND

    40% below its 50-day average. New closing low $2.19 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED2,240,578$12.4M
GEODE CAPITAL MANAGEMENT, LLCDOUBLED974,236$5.4M
STATE STREET CORPDOUBLED424,915$2.4M
NORTHERN TRUST CORPDOUBLED292,117$1.6M
GOLDMAN SACHS GROUP INCDOUBLED143,954$798.9K
CHARLES SCHWAB INVESTMENT MANAGEMENT INCDOUBLED113,625$630.6K
UBS Group AGTRIM42,208$234.3K
Vanguard Global Advisers, LLCTRIM15,335$85.1K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

9 analysts
Buy 78% rate it Buy or better
Strong Buy3Buy4Hold2Sell0Strong Sell0
12-month targets · 3 analysts

Price is below the lowest target. Median implies +356%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 14, 2026Jefferies
UPGRADE
UPGRADEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Aug 3, 2026
Kaul Inderjit
Director
AWARD12,147 sh
Jun 3, 2026
Ahlholm Frederick W
SVP, CFO and Secretary
AWARD680,000 sh
Jun 3, 2026
Kupfer David
Director
AWARD50,000 sh
Jun 3, 2026
VAN HEEK G JAN
Director
AWARD50,000 sh
Jun 3, 2026
Kaul Inderjit
Director
AWARD50,000 sh
Jun 3, 2026
HASLER HANS PETER
Director
AWARD50,000 sh
Jun 3, 2026
Luthringer Remy
CEO
AWARD1,690,700 sh
Jun 3, 2026
Laghrissi-Thode Fouzia
Director
AWARD50,000 sh

Earnings setup

Estimates
Nov 11
reports in 16 days
−$0.18
EPS estimate, this quarter
+20%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.18-$0.22–-$0.14+20.0%$0.00
Next Q-$0.20-$0.24–-$0.15+25.0%$0.00
Current FY-$0.57-$0.57–-$0.57-185.0%$0.00
Next FY-$0.42-$0.42–-$0.42—$0.00

Short side

FINRA· Sep 30, 2026
2,435,917
shares short
+0.6%
vs prior settlement
13.0
days to cover
≈5.1%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 31, 2026 Short interest report
Short Interest: NERV up 20% to 2.1M shares
Settlement 2026-08-31 | Days to cover: 6.35 | ≈4.42% of shares outstanding (est.)
Aug 12, 2026 SEC
Minerva Neurosciences appointed Anthony Aliquo as Chief Accounting Officer, relieving CFO Fred Ahlholm of the…
8-K — Impact 2/10
Aug 7, 2026 SEC
Minerva Neurosciences reported Q2 2026 financial results with a GAAP net income of $17.5M driven by a non-cash warrant…
8-K — Impact 4/10
Aug 3, 2026 Insider
Kaul Inderjit was granted 12,147 shares
Director
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
2,240,578 shares ($12.4M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — DOUBLED
974,236 shares ($5.4M)
Jun 3, 2026 Insider
Ahlholm Frederick W was granted 680,000 shares
SVP, CFO and Secretary
Jun 3, 2026 Insider
Kupfer David was granted 50,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
NERV Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Aug 31, 2026
Short interest
Short Interest: NERV up 20% to 2.1M shares
Settlement 2026-08-31 | Days to cover: 6.35 | ≈4.42% of shares outstanding (est.)
Aug 28, 2026
Press release
Minerva Neurosciences to Participate in Two Upcoming Investor Conferences
BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused…
Aug 14, 2026
Short interest
Short Interest: NERV down 28% to 1.8M shares
Settlement 2026-08-14 | Days to cover: 11.76 | ≈3.68% of shares outstanding (est.)
Aug 7, 2026
Earnings
Minerva Neurosciences Provides Second Quarter 2026 Financial Results and Business Updates
Confirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027
Aug 4, 2026
Earnings date
NERV Q2 2026 Earnings Scheduled — 2026-08-04

SecBot reports

7 filings · 2 press releases · 0 bullish · 2 bearish · 5 neutral
All NERV filing & press-release reports (9)